Results 41 to 50 of about 3,797 (192)

Ligand‐Based Pharmacophore Modeling and Structure‐Based Virtual Screening for Identifying Potential Therapeutic Agents Targeting the SARS‐CoV‐2 Spike Protein‐ACE2 Receptor Interaction

ChemMedChem, Volume 21, Issue 10, 27 May 2026.
A protocol guided by ligand‐based pharmacophore modeling and structure‐based virtual screening enabled the identification of 1H‐pyrazol‐5‐ol derivatives as novel inhibitors of the SARS‐CoV‐2 spike protein. The lead inhibitors, C‐3 and C‐4, could serve as templates for the design of potent antiviral agents targeting viral entry into host cells ...
Timoteo Delgado‐Maldonado, Gilberto Vargas‐Salas, Debasish Bandyopadhyay, Adriana Moreno‐Rodríguez, Eyra Ortiz‐Pérez, Gildardo Rivera   +5 more
wiley   +1 more source

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection:a phase IIb trial

, 2014
BACKGROUND & AIMS: Simeprevir (TMC435) is an oral NS3/4 protease inhibitor in phase III trials for chronic hepatitis C virus (HCV) infection. We performed a phase IIb, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and ...
Lenz, Oliver, Hirschfield, Gideon M, Ferenci, Peter, Jacobson, Ira, Poordad, Fred, Jane A, Scott, Gane, Edward, De Smedt, Goedele, Nikitin, Igor, Beumont-Mauviel, Maria, Foster, Graham R, Berg, Thomas, Fried, Michael W, Pockros, Paul J, Sekar, Vanitha, Hezode, Christophe, Peeters, Monika, Zeuzem, Stefan, Sinha, Rekha   +18 more
core   +1 more source

AKTIVITAS ANTIVIRUS HEPATITIS C EKSTRAK ETANOL 96% HERBA Phyllanthus niruri L. DAN KOMBINASI SIMEPREVIR IN VITRO [PDF]

, 2019
Hepatitis C virus (HCV) infection is the main cause of chronic liver disease, such as cirrhosis and liver cancer. Currently, the standard of hepatitis C virus treatment has been highly developed and achieved the level of Sustained Virological Response
MUHAMMAD DZUL AZMI AL-MUTAWAKKIL ‘ALALLAH, 051511133230
core   +1 more source

Small Molecule‐Based Conditional Gene Regulation: Advances and Applications

Chemistry–Methods, Volume 6, Issue 4, April 2026.
The precise, temporal, and reversible control of gene expression using small molecule ligands is crucial for understanding complex cellular functions and is rapidly advancing the field of synthetic biology. Small molecule‐mediated conditional gene regulation has widespread applications, including bio‐manufacturing, cellular reprogramming, gene therapy,
Mohd Afaque Ansari, Riddhima Sharma, Priyanka Swami, Ambadas B. Rode   +3 more
wiley   +1 more source

The Flavivirus NS3 Protein: Its Multifaceted Roles and Therapeutic Potential

Journal of Medical Virology, Volume 98, Issue 4, April 2026.
Abstract Mosquito‐borne flaviviruses are important human pathogenic viruses and can cause an array of symptoms ranging from asymptomatic to mild illness but can progress to severe disease conditions. Prominent members of the family Flaviviridae include Dengue virus, Zika virus, and West Nile virus, whose spread has increased globally due to the ...
Haejeong Lee, Hee Cho, Michaela U. Gack
wiley   +1 more source

Abordaje terapéutico en el Virus de la Hepatitis C: ¿Simeprevir o Sofosbuvir? [PDF]

, 2015
La prevalencia de personas infectadas con el Virus de la Hepatitis C (VHC) es de 140 millones en todo el mundo. La infección crónica además aumenta la probabilidad de aparición de cirrosis y carcinoma hepático.
Mencías Castillejo, Cristina
core   +1 more source

Simeprevir restores the anti-Staphylococcus activity of polymyxins

AMB Express, 2023
Methicillin-resistant Staphylococcus aureus (MRSA) infection poses a severe threat to global public health due to its high mortality. Currently, polymyxins are mainly used for the treatment of Gram-negative bacterial-related infection, while exhibiting ...
Yuan Wu, Pingyun Wu, Ruolan Wu, Huilong Li, Yao Duan, Chaoni Cai, Zixin Liu, Pengfei She, Di Zhang   +8 more
doaj   +1 more source

Disrupting Viral Persistence: CRISPR/Cas9‐Based Strategies for Hepatitis B and C Treatment, and Challenges

Journal of Cellular and Molecular Medicine, Volume 30, Issue 1, January 2026.
ABSTRACT Hepatitis B and C viruses (HBV and HCV) remain among the leading causes of liver disease worldwide. Current antiviral drugs, such as nucleotide analogues (NAs), can reduce the replication of new HBV and HCV infections but cannot completely eliminate chronic infections.
Meng‐Fan Li, Akmal Zubair, Safa Wdidi, Shan He   +3 more
wiley   +1 more source

The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients

Gut and Liver, 2018
Background/AimsAlthough daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged ≥75 years were excluded in the phase III trial. The present study aimed to evaluate the safety and efficacy of this
Shinya Taki, Hideyuki Tamai, Yoshiyuki Ida, Naoki Shingaki, Akira Kawashima, Ryo Shimizu, Kosaku Moribata, Takao Maekita, Mikitaka Iguchi, Jun Kato, Taisei Nakao, Masayuki Kitano   +11 more
doaj   +1 more source

Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection

, 2016
International audienceBACKGROUND & AIMS:We evaluated the combination of daclatasvir (pan-genotypic NS5A inhibitor) and simeprevir (NS3/4A protease inhibitor), with or without ribavirin, in hepatitis C virus genotype 1-infected patients.METHODS:This phase
Buti, Maria, Ouwerkerk-Mahadevan, Sivi, Cheung, Kin, Bronowicki, Jean-Pierre, Loustaud-Ratti, Veronique, Beumont-Mauviel, Maria, Makara, Mihaly, Mcphee, Fiona, Hughes, Eric A., Pruitt, Ronald, Al-Assi, M. Tarek, Noviello, Stephanie, Gea, Francisco, Thabut, Dominique, Olveira, Antonio, Gadano, Adrian, Petersen, Joerg, Bifano, Marc, Bourliere, Marc, Picchio, Gaston, Boparai, Navdeep, Pol, Stanislas, Hezode, Christophe, Banyai, Tivadar, Zeuzem, Stefan   +24 more
core   +1 more source